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Seoul National University 
 
Marine ecosystems contribute to a huge repository of pharmacologically active compounds. 
Palytoxin, one of the most toxic marine compounds, is known to be involved in the 
transformation of Na+/K+-ATPase into a cation channel inducing massive intracellular Na+ 
influx. Anti-cancer activity of palytoxin is an emerging area of research and especially 
palytoxin-induced cancer cell death mechanisms remain to be elucidated. Here we show that 
palytoxin induced cell death of various leukemia cell lines at low picomolar concentrations. 
Importantly, palytoxin did not affect viability of peripheral blood mononuclear cells (PBMC) 
cells from healthy donors and did not create systemic toxicity in zebrafish, thus 
demonstrating excellent differential toxicity. Cell death was characterized by nuclear 
condensation as demonstrated by Hoechst staining as well as by caspase activation 
demonstrated by western blot and luminescent caspase assays. Palytoxin triggers cleavage 
of initiator pro-caspases-8 and -9 as well as executioner pro-caspases-3 and -7 after 6 hours 
of treatment in a dose-dependent manner. As caspase activation is sensitive to pan-caspase 
inhibitor zVAD, we conclude that palytoxin induces apoptotic cell death. From a molecular 
point of view, palytoxin down-regulates anti-apoptotic Bcl-2 family proteins Mcl-1 and Bcl-
xL in a dose-dependent manner. MG-132, a proteasome inhibitor, was able to prevent 
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proteolysis of Mcl-1 whereas the three major proteasomal enzymatic activities were up-
regulated by palytoxin. Palytoxin-induced dephosphorylation of Bcl-2 further exacerbates 
the pro-apoptotic effect of Mcl-1 and Bcl-xL degradation. As okadaic acid could rescue cell 
death triggered by palytoxin, we hypothesize involvement of protein phosphatase (PP)2A in 
Bcl-2 phosphorylation and induction of apoptosis by palytoxin. Altogether, we provide here 
first evidence of the role of palytoxin as a very potent and promising cancer-specific 
cytotoxic agent acting at low picomolar concentrations.  
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LIST OF ABBREVIAIONS 
 
ATP  Adenosine triphosphate 
Bcl-2  B-cell leukemia/lymphoma 2 
Bcl-xL  B-cell lymphoma extra like large 
BID  Bcl-2 interacting domain death agonist 
BIM  Bcl-2 interacting mediator of cell death 
BSA  Bovine serum albumin 
BH-3  Bcl-2 Homology domain 3 
β-TrCP  β-transducin repeat containing protein 1 
Ca2+  Calcium ions  
Caspase Cysteine aspartate cleaving protein 
DMSO  Dimethylsulfoxide 
DPBS  Dulbecco’s phosphate buffered saline  
ERK1/2 Extracellular signal regulated kinase 1/2 
FBW7  F-box and WD repeat domain containing 7 
IC50  half maximal inhibitory concentration 
IL-8  Interleukin 8 
IκB-α  Inhibitor of kappa alpha 
Jurkat  Human T-cell lymphoma cell line   
K562  Human chronic myelogenous leukemia cell line 
MAPK  Mitogen-activated protein kinase 
Mcl-1  Myeloid cell leukemia 1 
MPER  Mammalian Protein Extraction Reagent 
Mule  Mcl-1 ubiquitin ligase E3 
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Na+/K+-ATPase Sodium-potassium adenosine triphosphatase 
NOXA  Phorbol-12-myristate-13-acetate-induced protein 1 
NF-κB  Nuclear factor-kappa B 
PUMA  p53 up-regulated modulator of apoptosis 
Ok  Okadaic Acid 
PBS  Phosphate buffered saline 
PBS-T  Phosphate buffered saline with Tween 
PBMC  Peripheral blood mononuclear cell 
pBcl-2   Phospho B-cell lymphoma 2 serine 70 residue 
PI  Propidium Iodide 
PTU  phenylthiourea 
PMSF  Phenylmethylsulphonyl fluoride  
PP2A  Protein phosphatase 2A 
PVDF  Polyvinylidene fluoride 
p38  p38 mitogen activated protein kinase 
RPMI  Roswell Park Memorial Institute  
SCF  Skp Cullin F-box containing 
SDS  Sodium dodecyl sulfate 
SDS-Page  SDS-Polyacrylamide Gel Electrophoresis 









Palytoxin is originally found in soft corals from tropical areas of the Pacific Ocean, for 
example from Hawaii where it was discovered in the tropical soft coral Palythoa species, a 
zoanthid [1]. Palytoxin was first characterized by the chemist Moore in 1981. This 
compound represents one of the largest polyether-type phycotoxins [1]. This non-peptidic 
toxin consists of a long polyhydroxylated and partially unsaturated chain of 129 carbon 
atoms and the aliphatic backbone contains 64 chiral centers [2]. Eight double bonds are able 
to exhibit cis/trans isomerism so that palytoxin could present over 1021 stereoisomers [3]. 
Structural analogs of palytoxin were also discovered and include ostreocin [4], ovatoxin [5], 
and mascarenotoxin [6]. The molecular weight of palytoxin ranges from 2658 to 2680 Da, 
depending on the Palythoa species from which it was obtained [2]. Palytoxin features both 
lipophilic and hydrophilic regions and is referred to as a super-carbon-chain compound, 
since it has the longest chain of continuous carbon atoms in any known natural product [7]. 
It is heat-stable, not inactivated by boiling and is stable in neutral aqueous solutions for 
prolonged periods, however a rapid decomposition occurs under acid or alkaline conditions 
leading to loss of its toxicity [2].  
Molecular action of palytoxin causes blockage of the Sodium-potassium adenosine 
triphosphatase (Na+/K+-ATPase) channel [8, 9]. This transmembrane protein exchanges 
three Na+ ions and two K+ ions using Adenosine triphosphate (ATP) hydrolysis as the driving 
force. The electrochemical gradient generated by the sodium pump for the maintenance of 
cell homeostasis is then inhibited by palytoxin. Palytoxin binds to the extracellular part of 
the Na+/K+-ATPase to transform the pump into a non-specific, permanently open ion channel 
causing membrane depolarization with massive increase of calcium ions (Ca2+) into the 
cytosol [10] strongly interfering with some vital functions. An alteration of intracellular 
cation concentration, in particular a calcium increase, is generally associated with cell death 
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as a modification in the distribution of these ions across the plasma membrane plays a key 
role in palytoxin-induced cell-type specific cytotoxic response [11].  
Further characterization of the mode of action of this compound would contribute to a better 
understanding of the molecular mechanism of cellular effects induced by palytoxin, which 
can be acting as a tool to probe the role of different types of signaling mechanisms involved 
in carcinogenesis. It has been already demonstrated to act as a skin tumor promoter able to 
modulate key signal transduction pathways involved in carcinogenesis [12]. In particular, it 
has been shown that palytoxin stimulates prostaglandin production from arachidonic acid 
and activates mitogen-activated protein kinases (MAPKs), including extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein 
kinase (p38) [13]. MAPKs mediate intracellular signaling associated with a variety of 
cellular activities such as proliferation, differentiation, survival, death and transformation 
[14]. Mitogenic agents, inflammatory cytokines or oxidative stress activate ERK and JNK 
signaling pathways. Subsequently, downstream MAPKs phosphorylate various protein 
substrates to eventually activate transcription factors that modulate inflammatory gene 
expression [15]. 
For our project, we focused our attention on the identification of cellular pathways and 
mechanisms involved in palytoxin-induced cell death in human leukemia cell lines. 
Intracellular signaling cascades induced by palytoxin may lead to activation of intrinsic and 
extrinsic apoptotic pathways triggered by alterations of the expression levels of pro- and 
anti-apoptotic Bcl-2 family proteins. Altogether our results show that palytoxin acts as a 
potent and promising cancer-specific cytotoxic agent at  low picomolar concentrations.  
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MATERIALS AND METHODS 
1. Cells and medium 
K562 (human chronic myelogenous leukemia, DSMZ, Germany), Jurkat (human T-lymphocyte, 
DSMZ, Germany) and U937 (human histiocytic lymphoma, DSMZ, Germany) cells were cultured 
in Roswell Institute Park Memorial Institute (RPMI) 1640 medium (Bio-Whittaker, Lonza) 
containing 1% (v/v) with a antibiotic/antimycotic mixture of penicillin 100U/ml, streptomycin 
100μg/ml, amphotericin B 0.25μg/ml (Bio-Whittaker, Lonza) at 37°C and 5% of CO2 in a humidified 
atmosphere. Cells were cultured and harvested every three days and treated with palytoxin in 
exponential growth phase. Cells were regularly tested against mycoplasma infection (MycoalertTM, 
Lonza USA) according to the manufacturer’s instructions. 
2. Compounds 
Palytoxin was a gift of Coral Biome, Marseille, France with a molecular mass of 2,680.14 g mol-1. 
Compound was received as a powder and solubilized in DMSO (Sigma-Aldrich, USA) and further 
diluted to get working aliquots at 1mM. Stocks and aliquots were stored at 4°C and protected against 
light and were used directly prior to the experiments. Etoposide was purchased from (Sigma-Aldrich, 
USA), dissolved in DMSO at a stock concentration of 50mM. Pan-caspase inhibitor, z-VAD FMK 
was purchased from Calbiochem (San Diego, USA) dissolved in DMSO and added 1h before at the 
concentration of 50μM. Protein phosphatase 2A inhibitor okadaic acid was purchased from 
Calbiochem (San Diego, USA), dissolved in DMSO at a stock concentration of 1mM. Proteasome 
inhibitor MG-132 was purchased from (Sigma-Aldrich, USA) dissolved in DMSO at a stock 
concentration of 10mM. MAP kinase inhibitors, SB202190 and PD98059 were purchased from 
Calbiochem (San Diego, CA, USA), dissolved in DMSO at a stock concentration of 100mM. 
Hydroquinone was purchased from (Sigma-Aldrich, USA), dissolved in DMSO at 10mM. Inhibitors 




Table I: Compounds used with corresponding working concentrations. 
Name Molecular mechanism Concentration Supplier 
Etoposide Caspase activator 100μM, 4h Sigma Aldrich 
z-VAD FMK Pan-Caspase inhibitor 10μm, 1h Calbiochem 
MG-132 Proteasome inhibitor 5μM, 1h Sigma Aldrich 
Paclitaxel Bcl-2 phosphorylation 500nM, 8h Sigma Aldrich 
SB202190 p38 inhibitor 10μM, 1h Calbiochem 
PD98059 ERK 1/2 inhibitor 10μM, 1h Calbiochem 
Okadaic Acid PP2A inhibitor 10μM, 1h Calbiochem 
Hydroquinone PP2A activator 10μM, 24h Sigma Aldrich 
 
3. Cell viability assessment  
Cell vitality was assessed in three different leukemia cell lines K562, Jurkat and U937. Each cell line 
was treated with different concentrations of palytoxin for 2, 4, 6, 8 hours in a dose and time-
dependent manner. Percentage of viability was evaluated using Trypan Blue exclusion test (0.2% 
Trypan Blue) and expressed as percentage of viability of cells without palytoxin treatment considered 
to be 100%.  
4. Caspase 3/7 activity assay  
Three x 105 U937 cells were seeded in 96-well plates in triplicate in 75μl for palytoxin treatment. 
Enzymatic activities of caspases- 3 and -7 were determined by using a luminescent Caspase-glo®3/7 
Assay) (Promega, South Korea). The assay was performed according the manufacturer’s instruction 
by adding 75μl of caspase-3/7 substrate to U937 cells in suspension. After one hour of incubation 
with DEVD-aminoluciferin substrate and luciferase, the luminescent signal was measured using an 
Centro LB 960 Microplate Luminometer (Berthold, South Korea).  
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5. Proteasome activity assay  
The Proteasome-Glo® cell based assay (Promega, South Korea) was used to evaluate the three major 
proteolytic enzyme activities (chymotrypsin-like, caspase-like, trypsin-like). The assays were 
performed as indicated in the manufacturer’s protocol. U937 cells, at a concentration of 106 cells/ml 
in RPMI 1640 medium containing 0.1% FCS, were treated at indicated concentrations of palytoxin. 
After an incubation period, 50μl of U937 cellular suspension were mixed with 50μl of assay reagent. 
The luminescence signal was measured on Centro LB 960 Microplate Luminometer (Berthold, South 
Korea). Proteasome signal was normalized to the number of viable cells performed in parallel. MG-
132 at 5μM (Sigma, USA) was used as a control for proteasomal inhibition.  
 
6. Cell lysate preparations and western blots 
Ten millions of U937 cells were seeded in 30ml in RPMI 1640 (Lonza, USA) with 10% foetal bovine 
serum (FBS) (Biowest, USA), 1% antibiotics (Lonza, USA). Cells were treated with palytoxin in a 
dose- and time-dependent manner as indicated. Cellular lysates were centrifuged at 22°C, 350g for 
7 minutes. After removal of the supernatant, pellets were washed in 1ml phosphate-buffered saline 
(PBS) and centrifuged again at 4°C, 350g for 7 minutes. Afterwards, supernatants were removed and 
pellets were directly stored at -80°C until use. The extraction was performed on ice to avoid 
denaturation of proteins. Whole-cell extracts were prepared with 5ml of mammalian protein 
Extraction reagent (M-PER), according to the manufacturer’s instructions (Pierce, Rockford USA). 
Extraction reagents include protease inhibitor 40μl/ml (Sigma, USA), phenylmethylsulphonyl 
fluoride (PMSF) 1mM (Roche, USA), sodium orthovandate 1mM (Sigma, USA), Phosphostop 
inhibitor 100μl/ml (Roche, USA) and M-PER in a final volume of 5ml. Depending on the pellet size, 
500μl of reagents were used for control pellets and 300μl for treated cell pellets. Dissolved pellets 




Proteins from total extracts were separated by size using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-Page) and transferred onto a Polyvinylidene 
fluoride (PVDF) membrane (GE healthcare) and blocked with 5% non-fat milk or 5% bovine 
serum albumin (BSA) in PBS-Tween overnight. Equal loading of samples was controlled by 
using β-actin. Blots were incubated with primary antibodies: anti β-actin (1/10000, Sigma-
Aldrich A5441), anti Caspase-3 (1/1000, Santa Cruz 56053), anti Caspase-7 (1/1000, Cell 
Signaling 9494) anti Caspase-8 (1/1000, Cell Signaling 9746), anti Caspase-9 (1/1000, Cell 
Signaling 9502), anti Mcl-1 (1/1000, Cell Signaling 4572), anti BID (1/1000, Cell Signaling 
2002), anti pBcl-2 ser70 (1/2000, Cell signaling 2827), anti Bcl-2 (1/2000, Calbiochem 
OP60), anti Bcl-xL (1/1000, BD biosciences 610212). All antibodies were diluted in a PBS-
Tween solution containing 5% BSA or 5% non-fat milk according to the provider’s protocols. 
After incubation with primary antibodies, membranes were washed 3 x 10 min with PBS-
Tween, followed by an incubation of 1h at RT with the corresponding secondary (HRP-
conjugated) antibodies. After washing 3 x 10 min with PBS-Tween, specific immunoreactive 
proteins were visualized by autoradiography using the ECL Plus Western Blotting Detection 











Table II: Antibodies used and working conditions   
Target Protein Supplier Origin Animal Primary Antibody Secondary Antibody 
β-Actin Sigma Aldrich # A5441 Mouse 
 
1/10,000 PBS-T 5% milk 
Room Temperature 1h. 
 
1/4,000 PBS-T 5% milk 
Room Temperature 1h 
Caspase 3 Santa Cruz SC 56053 Mouse 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/4,000 PBS-T 5% milk 
Room Temperature 1h 
Caspase 7 Cell Signaling # 9494 Mouse 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/4,000 PBS-T 5% milk 
Room Temperature 1h 
Caspase 8 Cell Signaling #9746 Mouse 
 
1/1000 PBS-T 5% BSA 
overnight 4˚C. 
 
1/4,000 PBS-T 5% milk 
Room Temperature 1h 
Caspase 9 Cell Signaling #9502 Rabbit 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/5,000 PBS-T 5% milk 
Room Temperature 1h 
Mcl-1 Cell Signaling #4572S Rabbit 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/4,000 PBS-T 5% milk 
Room Temperature 1h 
Bcl-xL BDBiosciences#610212 Rabbit 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/4,000 PBS-T 5% milk 
Room Temperature 1h 
Bcl-2 Calbiochem # OP60 Mouse 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/5,000 PBS-T 5% milk 
Room Temperature 1h 
BID Cell Signaling # 2002 Rabbit 
 
1/1000 PBS-T 5% milk 
overnight 4˚C. 
 
1/5,000 PBS-T 5% milk 
Room Temperature 1h 
pBcl-2 ser70 Cell Signaling #2827 Rabbit 
 
1/2000 PBs-T 5% BSA 
overnight 4˚C. 
 
1/5,000 PBS-T 5% milk 
Room Temperature 1h 
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7. Fluorescent microscopy analysis  
Three x 105 U937 cells were seeded in 24-well plates prior to palytoxin treatment. 300μl of 
treated cells were transferred into another 24-well plate for double staining with (1) the 
DNA-specific dye Hoechst 33342 (Sigma, USA) at 1μl/mg for 30 minutes of incubation and 
(2) propidium iodide (Sigma, USA) at 1.5μl/mg, diluted in PBS for 15 minutes of  incubation. 
Induction of apoptosis was assessed by fluorescent microscopy (Nikon TI-U, Seoul Korea) 
and expressed as the percentage of cells presenting condensed nuclei. Different stages of 
nuclear fragmentation were considered and at least 300 cells were counted in three 
independent fields. Microscopy images were analyzed using the ImageJ software 
(http://rsb.info.nih.gov/ij/docs/index.html). 
 
8. Systemic toxicity in zebrafish  
Zebrafish (Danio rerio) were obtained from the “Zebrafish International Resource Center” 
(ZIRC, OR) and maintained according to the zebrafish guidelines [16]. Adult fish were kept 
at 28.5°C on a 14 hour light/10 hour dark cycle similar to natural conditions and all embryos 
collected from natural mating as a unit of hours-post fertilization (hpf). 0.003% 
phenylthiourea (PTU) was added 14 hour before palytoxin treatment in order to remove 
pigmentation of zebrafish models. Embryos were then treated with indicated concentration 
of palytoxin in 24 hpf. Photographs were taken under light microscopy (Carl Zeiss Stereo 
microscope DV4, Seoul Korea) in order to quantify viable zebrafish. We thank Prof. Kyu-






9. Differential toxicity effects on healthy peripheral blood mononuclear 
cells 
Peripheral blood mononuclear cells (PBMC) were purified from fresh buffy coats of four 
healthy adult human donors (Red Cross, Luxembourg) using the standard Ficoll-Hypaque 
(GE Healthcare, Roosendaal, The Netherlands) density separation method. All healthy 
volunteer donors gave informed consent. After three washes in Dulbecco’s Phosphate 
Buffered Saline (DPBS, Lonza), cells were counted, and then re-suspended in RPMI 1640 
supplemented with 10% heat-inactivated fetal calf serum and 1% antibiotics-antimycotic at 
a cell density of 2 x 106 cells/ml. Cells were treated with palytoxin at indicated 
concentrations. After 8 hours of incubation, Trypan Blue assay was used to analyze PBMC 
cell viability.  
 
10. Statistical Analysis 
Data are presented as mean of at least three independent experiments with standard 
deviations. Statistical analysis was performed using the GraphPad Prism 6.0 software. One-
way and two-way ANOVA followed by Holm-Sidak multiple comparison tests were used 





1. Cytotoxic effect of palytoxin on human leukemia cells 
In order to assess the effect of palytoxin on the induction of cell death mechanisms in human 
leukemia cell lines, we first evaluated the effect of palytoxin on the cell growth of chronic 
leukemia (K562), acute T-cell leukemia (Jurkat), and histiocytic lymphoma (U937) cell lines 
(Figure 1.A, 1.B, 1.C). Leukemia cells were treated for 2, 4, 6, and 8h at different 
concentrations of palytoxin and viability was assessed by Trypan Blue exclusion assay. 
Figure 1.D shows that palytoxin strikingly inhibits leukemia cell growth in a dose-
dependent manner at low picomolar concentrations. Among our leukemia cell models, K562 
cells appeared to be more resistant to the palytoxin treatment (IC50: 52.1 ± 5.9pM) in 






Figure 1. Cytotoxic effect of Palytoxin on human leukemia cell lines 
(A) Effects of Palytoxin on human chronic leukemia K562 cell viability and proliferation 
(B) Effects of Palytoxin on human T-cell leukemia Jurkat cell viability and proliferation (C) 
Effects of Palytoxin on human histiocytic lymphoma U937 cell lines. (D) Calculated IC50 
values of three different human leukemia cell lines. Data are the mean of SD ± of three 
independent cultures. *p < 0.05, **p < 0.01, ***p <0.005, ****p <0.001 versus control.  
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2. Effect of palytoxin on healthy cells and organisms 
To evaluate the differential toxicity of palytoxin, we used both zebrafish and PBMCs from 
healthy donors (Figure 2.A, 2.B). Palytoxin was used a various concentrations to treat 
zebrafish embryos and larvae for 24h. Interestingly, we did not observe any toxicity nor 
alterations of the morphology of the yolk-sac or axial/tail malformations (Figure 2.A). 
Moreover we treated PBMCs from healthy donors with palytoxin at various concentrations 
and conducted Trypan Blue staining to assess cell integrity and viability (Figure 2.B). Even 
at tumor-promoting concentrations, palytoxin did not generate levels of toxicity comparable 
to leukemia models. Altogether this compound demonstrates a remarkable differential 
toxicity and selectively targets cancer cells. 
























































Figure 2. Effects of Palytoxin on zebrafish and healthy cells 
(A) Effects of palytoxin on developmental defects in zebrafish embryos. Zebrafish 
embryos were incubated with palytoxin at different concentrations from 1pM-100μM 
for 24h. Bar graph showing the rate of dead embryos in palytoxin-treated at 24 hpf (n=10 
fish examined). (B) Effect of palytoxin exposure on zebrafish morphology scale bar: 
20μM. Zebrafish are exposed to palytoxin did not exhibit moderate or severe defects of 
morphology. (C) Effect of palytoxin on the viability of healthy PBMCs. PBMCs from 
healthy donors were treated at indicated palytoxin concentrations for 24h. Results 
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correspond to the mean of ± SD of the quantification of three independent experiments. 
3. Palytoxin-induced cell death leads to caspase activation in U937 cells 
We subsequently investigated whether palytoxin was able to trigger caspase-dependent 
apoptotic cell death. Palytoxin-induced cell death was identified by changes in the nuclear 
morphology typical of apoptotic cell death, as demonstrated by Hoechst and PI staining. 
(Figure. 3A) As caspase activation is sensitive to pan-caspase inhibitor zVAD, we concluded 
that palytoxin induces apoptosis (Figure. 3B). Palytoxin induced the cleavage of the pro-
caspases-8 and -9 and executor pro-caspases-3 and -7 after 6h of treatment in a dose-
dependent manner (Figure. 3C). These results were further confirmed by luminescent assays 






Figure 3. Palytoxin-induced cell death leads to caspase activation in U937 cells 
(A) Hoechst/PI staining of palytoxin-treated cells. White arrows indicate cells displaying 
apoptotic features such as fragmented and condensed nuclei. Red arrows indicate PI positive 
cells undergoing late apoptosis and presenting necrotic morphology. (B) The percentage of 
apoptotic cells was evaluated by counting cells corresponding to apoptosis, late apoptosis, 
and necrosis. At least 100 cells in three random fields were counted by fluorescence 
microscopy. (C) Palytoxin activation of pro-caspasese-8, -9, -7, and -3 was investigated by 
western blot analysis (left; one of three independent experiments). Enzymatic activity of 
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caspases-3 and -7 were up-regulated in a dose-dependent manner. (right; data representative 
of three independent experiments (mean ± SD). Etoposide-treated cells (100μM, 4h) served 





4. Palytoxin down-regulates expression of anti-apoptotic Bcl-2 family 
proteins 
As the induction of apoptosis can be triggered by both inhibition of anti-apoptotic proteins 
or activation of pro-apoptotic mechanisms, we investigated the overall expression levels of 
selected proteins after palytoxin treatment (Figure. 4A). Expression level of myeloid cell 
leukemia-1 (Mcl-1) and B-cell lymphoma extra like large (Bcl-xL) are down-regulated in a 
dose-dependent manner whereas B-cell lymphoma 2 (Bcl-2) is affected to a lesser extend. 
Moreover, pro-apoptotic Bcl-2 interacting domain death agonist (BID) was truncated by 
palytoxin treatment (Figure. 4B), which implied that the amplification of intrinsic and 
extrinsic cell death pathway could be expected [17].  
 21 
 
Figure 4. Palytoxin down-regulates expression of anti-apoptotic Bcl-2 family proteins 
(A) Western blot analysis of anti-apoptotic Bcl-2 family protein expression inhibited by 
palytoxin after 6 hours of treatment. (B) Western blot analysis of the truncation of pro-
apoptotic protein BID induced by palytoxin.  Western blot results are representative of three-
independent experiments.  
5. Mcl-1 is down-regulated by palytoxin in a proteasome dependent 
manner 
It is well established that anti-apoptotic Mcl-1 can be down-regulated by several 
mechanisms [18] including caspase-mediated- or proteasome-dependent degradation [19]. 
Accordingly, we assessed palytoxin-induced Mcl-1 degradation in the presence of two 
prototypical inhibitors, zVAD and MG-132. Our results show that palytoxin-induced Mcl-1 
degradation is completely abrogated in the presence of MG-132 underlining the essential 
role of proteasome degradation in the effect of palytoxin (Figure. 5A). Unexpectedly, the 
three major proteasomal enzymatic activities including trypsin, chymotrypsin and caspase-
like were up-regulated after palytoxin treatment most likely further exacerbating the 
degradation of Mcl-1.  
In order to get deeper insight into the chronology of the molecular events triggered by 
palytoxin, we attempted to identify drivers of cell death rather than investigate the 
consequence of ongoing cellular demise. We used a kinetic approach to compare 
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proteasomal activation, Mcl-1 degradation and caspase activation. We obtained a rapid and 
significant activation of proteasomal activities prior to Mcl-1 degradation and caspase 
cleavage (Figure 5.B). In parallel, ATP levels were quantified in the cells and we also 
observed a rapid decline in ATP levels. (Figure 5.B). BID was cleaved at early steps which 
is in line with our hypothesis as BID requires polyubiquitination and proteasomal activation 
for its processing. Altogether, we conclude that palytoxin selectively targets essential cell 




Figure 5. Mcl-1 is ubiquitously down-regulated by palytoxin in a proteasome 
dependent manner  
(A) Palytoxin induced proteasome-dependent degradation of Mcl-1 in U937 cells. Band 
intensities were quantified using ImageJ software. Values represent the mean of ± SD for 
three independent experiments. The three major proteolytic activities of the 26S proteasome 
were assessed under the same conditions as the western blots. MG-132 at 5μM was used as 
a positive control for proteasomal inhibition in U937 cells. Asterisk indicates significant 
differences of treated versus control ***P< 0.005, ****P<0.001.  
(B) Kinetic analysis of assessment of three major proteasome activities in U937 cells. ATP 
levels were determined in order to normalize the three major proteasome activities induced 
by palytoxin. Expression of Mcl-1 degradation was evaluated by western blot analysis under 
the same conditions. The experiments are representative of three independent experiments. 
*P<0.05, **P<0.01, ***P<0.005, ****P<0.001.   
 
 24 
6. Bcl-2 serine 70 dephosphorylation induced by palytoxin is mediated 
through Protein Phosphatase 2A activation in U937 cells 
Our results also show that palytoxin affects Bcl-2 expression and phosphorylation levels 
witnessed by a discrete upshift of the band [20] (Figure. 6A). We investigated 
phosphorylation levels of Bcl-2 as it is well known that serine 70 phosphorylation is required 
for the pro-survival function of this protein [21]. Our results show a dose-dependent 
dephosphorylation of Bcl-2 contributing potentially to a loss of its pro-survival function 
(Figure. 6A). Serine 70 phosphorylation of Bcl-2 can be abrogated by phosphatase 
activation, mainly by protein phosphatase 2A (PP2A) activity [22]. Accordingly, in a next 
step, we used chemical inhibitors of selected cell signaling pathways including okadaic acid 
used at a concentration inhibiting specifically PP2A. Our results show that PP2A inhibition 
partially rescues U937 cells from palytoxin-induced cell death whereas other kinase 
pathways do not seem to be involved. (Figure. 6B)  
Altogether, we hypothesize that palytoxin-induced dephosphorylation of Bcl-2 by PP2A 
further exacerbates the pro-apoptotic effect of Mcl-1 and Bcl-xL degradation and that 





Figure 6. Bcl-2 serine70 dephosphorylation induced by palytoxin is mediated through 
protein phosphatase 2 activation in U937 cells  
(A) Palytoxin induces a dose-dependent dephosphorylation Bcl-2 at serine70 in U937 cells. 
Western blot is representative of three-independent experiments. Band intensities were 
quantified using ImageJ software. Paclitaxel (500nM, 8h) is used as positive control for 
multi-site phosphorylation of Bcl-2. ***P<0.005 versus control.  
(B) Okadaic acid, a protein phosphatase 2A (PP2A) inhibitor rescues U937 cells from 
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palytoxin-induced cell death. Hydroquinone (10μM, 24h) was used as positive control for 
PP2A activation. Cells were stained with Hoechst in order to analyze the nuclear 
morphology merged with phase contrast images using ImageJ. The percentage of cell death 
was evaluated by counting the number of cells undergoing various types of cellular death. 
Three independent fields of 100 cells were quantified. Data representative of three 






Figure 7. Schematic model of palytoxin-induced cell death 
Altogether, palytoxin acts as potent anti-leukemic agent at sub-tumor promoting 
concentrations, which leads to apoptotic cell death at IC50s at low picomolar concentrations 
in various leukemia cell modes with reduced differential and systemic toxicity.  
To achieve cell death, anti-apoptotic Mcl-1 and Bcl-xL proteins is degraded in a dose-
dependent manner. Mcl-1 is ubiquitously degraded by proteasomal up-regulation. Pro-
apoptotic BID is truncated and Bcl-2 serine70 is dephosphorylated by PP2A activation 







Here we demonstrated that palytoxin, one of the most toxic algal biotoxins known [23], is 
able to significantly induce apoptotic cell death at low picomolar concentrations in different 
types of leukemia. We focused our efforts on cell death mechanisms especially in acute 
myeloid leukemia (AML) U937 cells. Recent research showed that AML has abnormalities 
in one or more apoptotic pathways leading to a survival advantage over healthy cells [24].   
Indeed, palytoxin induced the most common and well defined form of programmed cell 
death in AML, apoptosis, a physiological process of cellular suicide in a caspase-dependent 
manner [25]. However, as we observed a small measureable amount of non-apoptotic cell 
death after caspase inhibition by zVAD, it is essential to determine in the future which type 
of secondary cell death mechanism the cell activates in the absence of apoptotic capacity 
[26]. In that sense investigation of activation of non-caspase proteases inducing calpains or 
cathepsins could be of interest [27], [28].  
Among Bcl-2 family proteins, Mcl-1 and Bcl-xL was found to be strongly down-regulated 
by palytoxin even at low picomolar concentrations. As we observed a consistent and early 
onset of BID truncation, the differential effect of extrinsic versus intrinsic cell death pathway 
is of interest and will be investigated by pathway specific caspase inhibitors [17].  
We have demonstrated that palytoxin regulates a rapid down-regulation of Mcl-1 protein 
without involving caspases-dependent modulation but rather a proteasome-dependent 
degradation of Mcl-1. Thus three major proteasome activities are up regulated by palytoxin 
possibly leading ubiquitin E3 ligases Skp Cullin F-box containing F-box WD repeat domain 
containing 7 (SCFFbw7), β-transducin repeat containing protein 1 (SCFβ-TrCP), and Mcl-1 
ubiquitin ligase E3 (Mule) [29], [30] promoting Usp9x (ubiquitin-specific peptidase 9, X-
linked) required for Mcl-1 deubiquitination [31]. Moreover, Bcl-2 homology domain-3 (BH-
3) only proteins including p53 up-regulated modulator of apoptosis (PUMA) or Phorbol-12-
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myristate-13-acetate-induced protein 1 (NOXA) induces degradation of Mcl-1 at the 
mitochondria level which also requires the E3 ligase Mule responsible for the 
polyubiquitination Mcl-1 [32]. The implication of NOXA in the regulation of Mcl-1 
proteasomal degradation will support our hypothesis as disruption of 26S proteasome 
function by various mechanism trigger the rapid accumulation of proteasome-dependent 
BH-3 only family and subsequent cell death induced by apoptosis [32].  
It will be interesting to investigate overexpression of Mcl-1 with plasmid constructs more 
specifically wild type and proteasome resistant isoforms of Mcl-1 [33]. Overexpression of 
these proteins will further allow us to strengthen the hypothesis of proteasomal degradation. 
Similarly, stably transfected Jurkat T cells expressing a form of mutated Bcl-2 (serine70, 
serine87, and threonine 69) will allow us to understand the role of Bcl-2 expression regulated 
by palytoxin in various models [34], [35].   
In this study, we also showed that inhibition of PP2A activity rescued palytoxin-induced cell 
death, which implies that phosphatases play a major role in cellular mechanisms activated 
by palytoxin [36]. PP2A has been described as a potential therapeutic target in Philadelphia 
chromosome-positive chronic myeloid leukemia or in acute myeloid leukemia where PP2A 
inactivation is a recurrent event [36]. Palytoxin could restore PP2A or related phosphatases 
to induce caspase-dependent apoptosis mediated through AKT and ERK1/2 pathways [37].      
In general, PP2A exerts both inhibitory and stimulatory effects on MAP kinase signaling 
pathways [38]. Previous findings suggest that palytoxin activates mitogen-activated protein 
kinase (MAPK) cascade including the three major groups, extracellular signal regulated 
protein kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinases/stress-activated protein kinase 
(JNK), p38 protein kinase in response to heat shock protein 27 (HSP27) phosphorylation in 
human breast adenocarcinoma (MCF-7) cell line [39]. In monocyte-derived human 
macrophages, palytoxin phosphorylates p38 MAPK and activates nuclear factor kappa B 
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(NF-κB) pathways by increasing the mRNA levels of inflammation-related genes like 
interleukin 8 (IL-8) and inhibitor of kappa alpha (IκB-α) leading NF-κB nuclear 
translocation [6]. These observations have led us to hypothesize that palytoxin may activate 
a pro-inflammatory signaling cascade in leukemia cell lines by regulation of kinases and 
phosphatases implicated in the inflammatory process [40].  
As palytoxin was described as a tumor promoter even though at higher concentrations [41], 
we intend to combine palytoxin at subtoxic concentration in co-treatment with known 
chemotherapeutic and experimental drugs including FMS-like tyrosine kinase 3 (FLT3) 
inhibitor [42], demethylating agents [43], and Bcl-2 family inhibitor in order to synergize 
anti-leukemic effects induced by apoptotic pathways [44].   
In conclusion, we demonstrate here the marine compound palytoxin rapidly induces cell 
death through apoptosis in human leukemia cell lines. While down regulating the expression 
of Mcl-1, palytoxin activates BID truncation eventually leading to intrinsic apoptotic 
pathway are caspase-dependent cell death mechanism. While additional analysis remains to 
be elucidated as various phosphatases could be involved, these findings show for the first 
time that palytoxin acts as an apoptotic inducer affecting leukemia cells, which makes 
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해양 천연물질은 독특한 유기화합구조로 구성 되어있으며 강력한 생리활성 효능을 
가지고 있어 항암신약 개발 물질로서 우수한 개발가치를 평가받고 있습니다. 그중 
해양 천연물 비펩디드성 물질로 가장 강력한 독성 효과를 나타내는 Palytoxin 물질
이 기존 보도된 연구에 의하면 Na+/K+-ATPase 구조에 결합하여 이온 농도를 변화시
킴으로 세포 신호전달을 조절하는 연구가 보도되었습니다.  
본인 이번 연구를 통하여 Palytoxin 물질이 다양한 백혈평 세포주들의 항암 억제효
과를 나타냄을 창출하였으며, 특별히 정상세포 Peripheral blood mononuclear (PBMC)
및 제브라피시 모델에서도 안정적인 독성효과를 나태냄으로 본 물질이 암세포를 선
택적으로 사멸시키는 효과를 발굴하였습니다.  
Palytoxin에 의한 항암사멸 효과를 규명하기 위해 신호전달을 연구한 결과, 본 물질
이 암세포 유도의 관련된 Caspases 단백질 및 효소 물질에 의하여 세포 사사멸 초래
하는 것을 발견하였습니다. 그 중 암세포 생존과 사멸을 조절하는 MCl-1, Bcl-xl 단
백질들을 포로테아좀의 기능을 촉진시킴으로 분해하는 효과를 규명하였으며, Bcl-
2 serine70 단백질 구조의 PP2A에 탈인산화 기능으로 의하여 생존을 억제하는 효과
를 규명하였습니다.  
결론적은로 본 연구를 통해 Palytoxin 천연해양물질이 항암신약으로서 우수한 효능
을 가지고 있음을 증명하고, 낮은 농도에서도 우수한 약리독성 안정성을 나타내는 
물질임을 연구를 통하여 증명하게 되었습니다.  
주요여: 해양천연물, Palytoxin, 세포사멸, 백혈병 
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